Arizona State University will lead a four-year, $5 million expanded initiative sponsored by the National Institutes of Health to discover proteins, or biomarkers, to help predict cardiovascular disease and to assess potential new treatments in people with type 2 diabetes.
Nearly 26 million Americans have diabetes, the seventh leading cause of death in the U.S. The disease is a major cause of heart disease, stroke, kidney disease, blindness and amputation. The national cost of diabetes was an estimated $174 billion in 2007, the majority for direct medical costs.
Controlling blood sugar (glucose) levels is vital for treating diabetes and preventing or slowing complications. However, heart attack and stroke remain leading causes of death in diabetes.
“There are no standard biomarkers to identify people with type 2 diabetes who are more likely to develop cardiovascular disease. We assembled a highly integrated, multidisciplinary research team to discover, validate and translate novel protein biomarkers for cardiovascular complications in type 2 diabetes and their use in drug development,” said project leader Randy Nelson, director of the Molecular Biosignatures Analysis Unit at ASU’s Biodesign Institute. Nelson is an expert in proteomics, a scientific discipline that studies the structure and function of the proteins that constitute an organism.
The project is supported under an NIH program that encourages scientists from different disciplines to collaborate on a single, critically important research problem that has the potential to advance clinical research.
“Identifying markers to predict heart and blood vessel diseases in people with type 2 diabetes is challenging but important,” said Salvatore Sechi, Ph.D., who oversees the project for the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. “We are looking to the project’s team of experts in proteomics, drug development, biostatistics and clinical studies to advance the difficult search for markers that may be useful for both diagnosis and for assessing potential new drug therapies.” Read more…